Lactic Acid Bacteria Strains for Blood Glucose Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral antidiabetic drugs for hyperglycemia often cause side effects like hypoglycemia and gastrointestinal disorders, and lose effectiveness over time, necessitating insulin injections, which significantly degrade the quality of life for patients with diabetes.
Innovation Solution
Development of food and pharmaceutical compositions containing specific lactic acid bacteria strains, such as GL-104 strain of Lactobacillus reuteri and AP-32 strain of Lactobacillus salivarius subsp. salicinius, which modulate blood glucose levels and are deposited in the China Center For Type Culture Collection, to provide a safe and long-term solution for diabetes management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral antidiabetic drugs are used to treat hyperglycemia, then blood glucose levels can be controlled, but side effects such as hypoglycemia and gastrointestinal disorders occur
Solution Approach 1:
The patent introduces lactic acid bacteria strains (Lactobacillus reuteri GL-104 and Lactobacillus salivarius AP-32) as intermediary organisms that modulate blood glucose through biological mechanisms rather than direct pharmacological action. These probiotics act as mediators between dietary intake and blood glucose regulation, producing beneficial effects without the harmful side effects of conventional drugs.
Solution Approach 2:
The patent replaces the chemical/pharmacological mechanism of antidiabetic drugs with a biological mechanism using live lactic acid bacteria strains. Instead of using chemical compounds that directly affect blood glucose levels, the invention uses living microorganisms that modulate glucose metabolism through their metabolic activities and interactions with the host's gut microbiota.
2Reliability
If oral antidiabetic drugs are used long-term, then initial blood glucose control is achieved, but the drugs fail to work after long-term use
Solution Approach 1:
The patent employs dynamic probiotic strains that can adapt and continue their glucose-modulating functions over time. The lactic acid bacteria maintain their metabolic activities and continue to produce beneficial effects through ongoing interactions with the host's digestive system, preventing the tolerance development seen with conventional drugs.
Solution Approach 2:
The lactic acid bacteria strains serve themselves by continuously reproducing and maintaining their metabolic functions within the host's gut environment. They self-regulate their population and metabolic activities to sustain long-term blood glucose modulation without requiring external intervention or suffering from diminishing returns.
3Reliability
If insulin injection is used after oral drugs fail, then blood glucose control is maintained, but quality of life significantly degrades
Solution Approach 1:
The patent uses orally administrable lactic acid bacteria as intermediaries to achieve blood glucose control without requiring insulin injections. This oral probiotic approach serves as an intermediary solution that maintains glucose control effectiveness while avoiding the invasive nature and quality of life degradation associated with daily insulin injections.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These lactic acid bacteria strains effectively modulate blood glucose, reduce insulin resistance, and improve cholesterol and triacylglycerol levels, offering a safer alternative to conventional antidiabetic drugs with fewer side effects and improving the quality of life for diabetes patients.
Implementation Method 1
lactic acid bacteria strains... modulate blood glucose
Data Source
AI summary
A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.